Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$162.78 USD
-0.44 (-0.27%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $162.99 +0.21 (0.13%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$162.78 USD
-0.44 (-0.27%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $162.99 +0.21 (0.13%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum D VGM
Zacks News
Unlocking Q2 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Johnson & Johnson (JNJ) closed at $149.43, indicating a +1.62% shift from the previous trading day.
Will Q2 Earnings Power Dow ETFs?
by Sweta Killa
The Dow Jones is underperforming the other large-cap indices, such as the S&P 500 and Nasdaq Composite Index. Can the upcoming Q2 earnings help the index to catch up?
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
by Kinjel Shah
A new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However, those who already own the stock may stay invested as the company is generating decent sales growth.
Intuitive Surgical (ISRG) Rises 10% in a Month: What's Next?
by Indrajit Bandyopadhyay
Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
by Zacks Equity Research
AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
by Zacks Equity Research
Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $147.19, moving -1.29% from the previous trading session.
Here's Why You Should Consider Buying Alvotech (ALVO) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Alvotech (ALVO) stock now may turn out to be a prudent move.
Do Options Traders Know Something About Johnson & Johnson (JNJ) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Johnson & Johnson (JNJ) stock based on the movements in the options market lately.
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
by Kinjel Shah
FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
by Zacks Equity Research
J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
by Zacks Equity Research
Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Johnson & Johnson (JNJ) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $145.65, marking a -0.21% move from the previous day.
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
by Zacks Equity Research
Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Johnson & Johnson (JNJ) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $146.76, moving -0.25% from the previous trading session.
The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Verizon, Taylor Devices and Frequency Electronics
by Zacks Equity Research
Broadcom, Johnson & Johnson, Verizon, Taylor Devices and Frequency Electronics are included in this Analyst Blog.
Earnings Season Update and Analyst Reports for Broadcom, JNJ & Verizon
by Sheraz Mian
Today's Research Daily features an earnings season update and new research reports on Broadcom (AVGO), Johnson & Johnson (JNJ) and Verizon (VZ), as well as two micro-cap stocks Taylor Devices, Inc. (TAYD) and Frequency Electronics, Inc. (FEIM).